| Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding AM Owsianka, JM Timms, AW Tarr, RJP Brown, TP Hickling, A Szwejk, ... Journal of virology 80 (17), 8695-8704, 2006 | 315 | 2006 |
| Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33 AW Tarr, AM Owsianka, JM Timms, PC McClure, RJP Brown, TP Hickling, ... Hepatology 43 (3), 592-601, 2006 | 214 | 2006 |
| A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo TP Hickling, H Bright, K Wing, D Gower, SL Martin, RB Sim, R Malhotra European journal of immunology 29 (11), 3478-3484, 1999 | 175 | 1999 |
| Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics J Davda, P Declerck, S Hu-Lieskovan, TP Hickling, IA Jacobs, J Chou, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 121 | 2019 |
| Improving the pharmacokinetic properties of biologics by fusion to an anti-HSA shark VNAR domain MR Müller, K Saunders, C Grace, M Jin, N Piche-Nicholas, J Steven, ... MAbs 4 (6), 673-685, 2012 | 106 | 2012 |
| Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33 AW Tarr, AM Owsianka, D Jayaraj, RJP Brown, TP Hickling, WL Irving, ... Journal of General Virology 88 (11), 2991-3001, 2007 | 100 | 2007 |
| Mannan binding lectin and viral hepatitis KS Brown, SD Ryder, WL Irving, RB Sim, TP Hickling Immunology letters 108 (1), 34-44, 2007 | 91 | 2007 |
| Lung surfactant protein A provides a route of entry for respiratory syncytial virus into host cells TP HICKLING, R MALHOTRA, H BRIGHT, W MCDOWELL, ED BLAIR, ... Viral immunology 13 (1), 125-135, 2000 | 91 | 2000 |
| Therapeutic outcomes, assessments, risk factors and mitigation efforts of immunogenicity of therapeutic protein products L Yin, X Chen, P Vicini, B Rup, TP Hickling Cellular Immunology 295 (2), 118-126, 2015 | 86 | 2015 |
| Human lung surfactant protein A exists in several different oligomeric states: oligomer size distribution varies between patient groups TP Hickling, R Malhotra, RB Sim Molecular Medicine 4, 266-275, 1998 | 77 | 1998 |
| The development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models S Palsson, TP Hickling, EL Bradshaw-Pierce, M Zager, K Jooss, ... BMC systems biology 7, 1-19, 2013 | 76 | 2013 |
| Collectins and their role in lung immunity TP Hickling, H Clark, R Malhotra, RB Sim Journal of Leucocyte Biology 75 (1), 27-33, 2004 | 75 | 2004 |
| Immunoassay methods used in clinical studies for the detection of anti-drug antibodies to adalimumab and infliximab B Gorovits, DJ Baltrukonis, I Bhattacharya, MA Birchler, D Finco, ... Clinical & Experimental Immunology 192 (3), 348-365, 2018 | 70 | 2018 |
| A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 1—theoretical model X Chen, TP Hickling, P Vicini CPT: pharmacometrics & systems pharmacology 3 (9), 1-9, 2014 | 64 | 2014 |
| Specific interaction of hepatitis C virus glycoproteins with mannan binding lectin inhibits virus entry KS Brown, MJ Keogh, AM Owsianka, R Adair, AH Patel, JN Arnold, ... Protein & cell 1, 664-674, 2010 | 64 | 2010 |
| Severe fibrosis in hepatitis C virus-infected patients is associated with increased activity of the mannan-binding lectin (MBL)/MBL-associated serine protease 1 (MASP-1) complex KS Brown, MJ Keogh, N Tagiuri, MJ Grainge, JS Presanis, SD Ryder, ... Clinical & Experimental Immunology 147 (1), 90-98, 2007 | 61 | 2007 |
| Contribution of enhanced engagement of antigen presentation machinery to the clinical immunogenicity of a human interleukin (IL)-21 receptor-blocking therapeutic antibody L Xue, T Hickling, R Song, J Nowak, B Rup Clinical & Experimental Immunology 183 (1), 102-113, 2016 | 52 | 2016 |
| Immunogenicity of biosimilars for rheumatic diseases, plaque psoriasis, and inflammatory bowel disease: a review from clinical trials and regulatory documents V Strand, J Gonçalves, TP Hickling, HE Jones, L Marshall, JD Isaacs BioDrugs 34, 27-37, 2020 | 50 | 2020 |
| A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics X Chen, T Hickling, E Kraynov, B Kuang, C Parng, P Vicini The AAPS journal 15, 1141-1154, 2013 | 46 | 2013 |
| A mechanistic, multiscale mathematical model of immunogenicity for therapeutic proteins: part 2—model applications X Chen, TP Hickling, P Vicini CPT: pharmacometrics & systems pharmacology 3 (9), 1-10, 2014 | 45 | 2014 |
